Apyx Medical Corporation to Release First Quarter of Fiscal Year 2025 Financial Results on May 8, 2025
Apyx Medical (NASDAQ: APYX), manufacturer of proprietary helium plasma and radiofrequency technology Renuvion®, has scheduled its first quarter fiscal year 2025 financial results release for May 8, 2025, before market open.
The company will host a conference call at 8:00 a.m. Eastern Time on the same day, featuring a management discussion and Q&A session. Interested parties can join via phone (800-717-1738 for domestic, 646-307-1865 for international) using access code 63341, or through the company's webcast link and Investor Relations website section.
Apyx Medical specializes in advanced energy technology, particularly its Helium Plasma Platform Technology marketed as Renuvion® for cosmetic surgery and J-Plasma® for hospital surgical markets. The company's products are supported by over 90 clinical publications.
Apyx Medical (NASDAQ: APYX), produttore della tecnologia proprietaria a plasma di elio e radiofrequenza Renuvion®, ha programmato la pubblicazione dei risultati finanziari del primo trimestre dell'anno fiscale 2025 per l'8 maggio 2025, prima dell'apertura dei mercati.
La società terrà una conference call alle 8:00 ora della costa orientale degli Stati Uniti nello stesso giorno, con una presentazione della direzione e una sessione di domande e risposte. Gli interessati potranno partecipare telefonicamente (800-717-1738 per chiamate nazionali, 646-307-1865 per internazionali) utilizzando il codice di accesso 63341, oppure tramite il link webcast dell'azienda e la sezione Investor Relations del sito web.
Apyx Medical è specializzata in tecnologie energetiche avanzate, in particolare nella sua piattaforma a plasma di elio commercializzata come Renuvion® per la chirurgia estetica e J-Plasma® per il mercato chirurgico ospedaliero. I prodotti dell'azienda sono supportati da oltre 90 pubblicazioni cliniche.
Apyx Medical (NASDAQ: APYX), fabricante de la tecnología propietaria de plasma de helio y radiofrecuencia Renuvion®, ha programado la publicación de sus resultados financieros del primer trimestre del año fiscal 2025 para el 8 de mayo de 2025, antes de la apertura del mercado.
La compañía realizará una conferencia telefónica a las 8:00 a.m., hora del Este, el mismo día, que incluirá una presentación de la dirección y una sesión de preguntas y respuestas. Los interesados pueden unirse por teléfono (800-717-1738 para llamadas nacionales, 646-307-1865 para internacionales) usando el código de acceso 63341, o a través del enlace webcast de la empresa y la sección de Relaciones con Inversionistas en el sitio web.
Apyx Medical se especializa en tecnología energética avanzada, especialmente en su Plataforma de Plasma de Helio comercializada como Renuvion® para cirugía estética y J-Plasma® para mercados quirúrgicos hospitalarios. Los productos de la empresa cuentan con el respaldo de más de 90 publicaciones clínicas.
Apyx Medical (NASDAQ: APYX)는 독자적인 헬륨 플라즈마 및 고주파 기술인 Renuvion®의 제조업체로, 2025 회계연도 1분기 재무 결과를 2025년 5월 8일 장 시작 전 발표할 예정입니다.
회사는 같은 날 동부 표준시 기준 오전 8시에 경영진 발표 및 질의응답 세션이 포함된 컨퍼런스 콜을 진행합니다. 관심 있는 분들은 국내 전화(800-717-1738), 국제 전화(646-307-1865)로 접속 코드 63341을 사용해 참여하거나 회사 웹캐스트 링크 및 투자자 관계 웹사이트를 통해 참여할 수 있습니다.
Apyx Medical은 첨단 에너지 기술, 특히 미용 수술용 Renuvion® 헬륨 플라즈마 플랫폼 기술과 병원 수술 시장용 J-Plasma®를 전문으로 합니다. 회사 제품은 90건 이상의 임상 논문으로 뒷받침되고 있습니다.
Apyx Medical (NASDAQ : APYX), fabricant de la technologie propriétaire à plasma d’hélium et radiofréquence Renuvion®, a programmé la publication de ses résultats financiers du premier trimestre de l’exercice 2025 pour le 8 mai 2025, avant l’ouverture des marchés.
La société organisera une conférence téléphonique le même jour à 8h00, heure de l’Est, comprenant une présentation de la direction et une session de questions-réponses. Les intéressés peuvent participer par téléphone (800-717-1738 pour les appels nationaux, 646-307-1865 pour les appels internationaux) en utilisant le code d’accès 63341, ou via le lien webcast de l’entreprise et la section Relations Investisseurs du site web.
Apyx Medical est spécialisée dans les technologies énergétiques avancées, notamment sa plateforme à plasma d’hélium commercialisée sous le nom Renuvion® pour la chirurgie esthétique et J-Plasma® pour les marchés chirurgicaux hospitaliers. Les produits de l’entreprise sont soutenus par plus de 90 publications cliniques.
Apyx Medical (NASDAQ: APYX), Hersteller der proprietären Heliumplasma- und Radiofrequenztechnologie Renuvion®, hat die Veröffentlichung der Finanzergebnisse für das erste Quartal des Geschäftsjahres 2025 für den 8. Mai 2025 vor Börsenöffnung angekündigt.
Das Unternehmen wird am selben Tag um 8:00 Uhr Eastern Time eine Telefonkonferenz mit einer Managementpräsentation und einer Fragerunde abhalten. Interessierte können telefonisch teilnehmen (800-717-1738 für Inland, 646-307-1865 für international) unter Verwendung des Zugangscodes 63341 oder über den Webcast-Link des Unternehmens und den Bereich Investor Relations auf der Webseite.
Apyx Medical ist auf fortschrittliche Energietechnologie spezialisiert, insbesondere auf die Helium-Plasma-Plattformtechnologie, die als Renuvion® für die kosmetische Chirurgie und J-Plasma® für den Krankenhaus-Operationsmarkt vermarktet wird. Die Produkte des Unternehmens werden durch über 90 klinische Veröffentlichungen unterstützt.
- None.
- None.
CLEARWATER, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ: APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that financial results for the first quarter of fiscal year 2025 will be released before markets open on Thursday, May 8th.
Management will host a conference call at 8:00 a.m. Eastern Time on Thursday, May 8th to discuss the results of the quarter, and to host a question-and-answer session. To listen to the call by phone, interested parties may dial 800-717-1738 (or 646-307-1865 for international callers) and provide access code 63341. Participants should ask for the “Apyx Medical Corporation Call”. A live webcast of the call will be accessible via the following link: Apyx Medical Earnings Webcast and via the Investor Relations section of the Company’s website, where it will be archived for future reference.
Investor Relations Contact:
Jeremy Feffer
Managing Director
LifeSci Advisors
OP: 212-915-2568
jfeffer@lifesciadvisors.com
About Apyx Medical Corporation:
Apyx Medical Corporation is an advanced energy technology company with a passion for elevating people’s lives through innovative products, including its Helium Plasma Platform Technology products marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market. Renuvion and J-Plasma offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The effectiveness of Renuvion and J-Plasma are supported by more than 90 clinical publications. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. For further information about the Company and its products, please refer to the Apyx Medical Corporation website at www.ApyxMedical.com
FAQ
When will Apyx Medical (APYX) release Q1 2025 earnings?
How can investors join APYX's Q1 2025 earnings call?
What are Apyx Medical's main products in the medical device market?
How many clinical publications support Apyx Medical's technology?
